000			01847 a2200529 4500
005			20250514200234.0
264		0	_c20041130
008			200411s 0 0 eng d
022			_a0903-1936
024	7		_a10.1183/09031936.04.00100303 _2doi
040			_aNLM _beng _cNLM
100	1		_aLee, D K C
245	0	0	_aMontelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. _h[electronic resource]
260			_bThe European respiratory journal _cAug 2004
300			_a226-30 p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAcetates _xadministration & dosage
650	0	4	_aAdministration, Inhalation
650	0	4	_aAdult
650	0	4	_aAspirin _xadverse effects
650	0	4	_aAsthma _xchemically induced
650	0	4	_aConfidence Intervals
650	0	4	_aCross-Over Studies
650	0	4	_aCyclopropanes
650	0	4	_aCysteine _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDouble-Blind Method
650	0	4	_aDrug Administration Schedule
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLeukotrienes _xmetabolism
650	0	4	_aLysine _xadverse effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNasal Provocation Tests
650	0	4	_aPeak Expiratory Flow Rate
650	0	4	_aQuinolines _xadministration & dosage
650	0	4	_aReference Values
650	0	4	_aReproducibility of Results
650	0	4	_aSpirometry
650	0	4	_aSulfides
700	1		_aHaggart, K
700	1		_aRobb, F M
700	1		_aLipworth, B J
773	0		_tThe European respiratory journal _gvol. 24 _gno. 2 _gp. 226-30
856	4	0	_uhttps://doi.org/10.1183/09031936.04.00100303 _zAvailable from publisher's website
999			_c15029910 _d15029910